Latest News and Press Releases
Want to stay updated on the latest news?
-
Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial...
-
Er-Kim signs distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region
-
Know Rare launches HealthStoryAI app for people living with rare disease, leveraging the latest natural language processing (NLP) technology
-
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
-
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
-
Results from pivotal study published in Diagnostics journalConfirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher diseaseCould predict clinical course of...
-
BERLIN, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Therapien für seltene genetische...
-
Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World CENTOGENE’s FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic...
-
Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosisCombines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with...
-
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...